Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2013

01-04-2013 | Review

A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer

Authors: Iben Kümler, Nils Brünner, Jan Stenvang, Eva Balslev, Dorte L. Nielsen

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Login to get access

Abstract

Following treatment with anthracyclines and taxanes, few established options exist for the treatment of metastatic breast cancer (MBC). Although the topoisomerase 1 inhibitors irinotecan, etirinotecan, and topotecan have been used in clinical trials on MBC, the drugs have never been introduced as standard treatment for the disease. We performed a systematic review on topoisomerase 1 inhibitors in MBC and found 22 prospective trials and three retrospective ones. No phase III trials were identified. Only one study was randomized, and generally studies were small. Response rates (RR) for irinotecan monotherapy varied from 5 to 23 %, whereas RRs for etirinotecan were 26–32 %. Only four trials on topotecan monotherapy were reported with RRs of 6–31 %. Combination therapy with irinotecan and various chemotherapeutics resulted in RRs ranging from 14 to 64 %, whereas irinotecan combined with biologic agents showed very limited effect. Topotecan was studied in combination with either another chemotherapeutic or a biologic agent in two trials, both studies failing to show any effect of topotecan. The most common grade 3 and 4 adverse events (AE) for irinotecan were neutropenia, diarrhea, and nausea/vomiting. The dosing schedule appears to affect the toxicity profile of the drug. Hematologic AEs are most frequently reported for topotecan. Conclusively, topotecan does not seem to be efficient in the treatment of MBC. Irinotecan seem to be effective in some patients previously treated with anthracyclines and taxanes. RRs of 23 % for irinotecan and 32 % for etirinotecan are comparable to some of the more commonly used treatments for MBC. However, a large proportion of patients do not respond, thus emphasizing the need for a biomarker predictive of response to irinotecan in order to introduce this drug as the standard treatment for MBC.
Literature
1.
Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179–1183. doi:1093/​jnci/​djn233 PubMedCrossRef
2.
Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS (2009) International guidelines for management of metastatic breast cancer: combination vs. sequential single-agent chemotherapy. J Natl Cancer Inst 101(17):1174–1181. doi:10.​1093/​jnci/​djp235 PubMedCrossRef
3.
4.
5.
6.
7.
8.
Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD (2012) A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res 19(1):268–278. doi:10.​1158/​1078-0432.​CCR-12-1201 PubMedCrossRef
9.
10.
11.
12.
13.
Bittoni A, Maccaroni E, Scartozzi M, Berardi R, Cascinu S (2010) Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. Eur Rev Med Pharmacol Sci 14(4):309–314PubMed
14.
Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G (2010) Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 33(5):461–464. doi:10.​1097/​COC.​0b013e3181b4e3b0​ PubMedCrossRef
15.
16.
17.
18.
19.
Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H (2011) A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 67(6):1225–1237. doi:10.​1007/​s00280-010-1410-1 PubMedCrossRef
20.
Ikeda H, Koshiba R (2000) A pilot study of irinotecan hydrochloride for metastatic breast cancer–efficacy as a salvage therapy. Gan To Kagaku Ryoho 27(5):723–727PubMed
21.
Ikeda M, Kurebayashi J, Sonoo H, Oota Y, Fujii S, Shimo T, Miyake A, Seki M, Souda M, Nomura T, Yamamoto Y, Shiiki S, Nakashima K, Tanaka K (2009) Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer. Gan To Kagaku Ryoho 36(5):773–777PubMed
22.
Okubo S, Kurebayashi J, Sonoo H, Hirono M, Nomura N, Udagawa K, Yamamoto Y, Ikeda M, Nakashima K, Tanaka K (2003) Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer. Gan To Kagaku Ryoho 30(10):1441–1445PubMed
23.
Doihara H, Takashima S, Yokoyama N (1994) Four cases of recurrent breast cancer effectively treated by the new antitumor agent, CPT-11 (irinotecan). Gan To Kagaku Ryoho 21(8):1263–1266PubMed
24.
Murata T, Fujii M, Aoki M, Oda K (2011) A case of spindle cell carcinoma of the breast, in which irinotecan was effective against respiratory failure due to pulmonary metastases. Gan To Kagaku Ryoho 38(3):431–434PubMed
25.
Wolff AC, O’Neill A, Kennedy MJ, Stewart JA, Gradishar WJ, Lord RS 3rd, Davidson NE, Wood WC (2005) Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193. Clin Breast Cancer 6(4):334–339. doi:10.​3816/​CBC.​2005.​n.​037 PubMedCrossRef
26.
Fleming GF, Kugler JW, Hoffman PC, Ansari R, Bitran JD, Klepsch A, Malone D, Fasanmade AA, Ratain MJ, Vokes EE (1998) Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. J Clin Oncol 16(6):2032–2037PubMed
27.
Chang H, Han S, Oh D, Im S, Kim T, Bang Y (2009) Combination chemotherapy of irinotecan with fluoropyrimidine in taxane, anthracycline and fluoropyrimidine-pretreated metastatic breast cancer. J Clin Oncol 27 (Suppl):abstract e12003
28.
Espinós J, Olier-Garate C, Aramendia JM, Hidalgo OF, Reyna C, De La Cruz S, del Barrio A, Garcia-Foncillas J (2008) Efficacy of the combination of irinotecan and bevacizumab in heavely pretreated metastatic breast cancer. J Clin Oncol 26 (May 20 suppl):abstract 12001
29.
Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL (2008) Phase II study of sequentially administered low-dose mitomycin-C(MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann Oncol 19(8):1417–1422. doi:10.​1093/​annonc/​mdn154 PubMedCrossRef
30.
Vukelja S, O′Shaughnessy J, Campos L, Vahdat J, Blum J, Yardley P, Mainwaring F, Senecal R, Benner R, Denis L, Perez E (2005) Activity of oral irinotecan n metastatic breast cancer patients after prior anthracycline, taxane and capecitabine: phase 2 study results. J Clin Oncol 23(16S):619
31.
Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA (2010) N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol 21(3):493–497. doi:10.​1093/​annonc/​mdp328 PubMedCrossRef
32.
Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP (2011) Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105(3):613–620. doi:10.​1007/​s11060-011-0629-y PubMedCrossRef
33.
Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, Morinaga R, Terashima M, Miyazaki M, Okamoto I, Nishida Y, Tominaga S, Tokunaga Y, Yamaguchi M, Sakamoto J, Nakayama T, Nakagawa K (2011) Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B. Breast Cancer 6(8):e23849. doi:10.​1007/​s12282-011-0316-z
34.
Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22(14):2849–2855. doi:10.​1200/​JCO.​2004.​10.​047 PubMedCrossRef
35.
Shigeoka Y, Itoh K, Igarashi T, Ishizawa K, Saeki T, Fujii H, Minami H, Imoto S, Sasaki Y (2001) Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens. Jpn J Clin Oncol 31(8):370–374PubMedCrossRef
36.
Garcia AA, Awada A, Chan S, Jerusalem G, Coleman RE, Huizing MT, Mehdi A, O′Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young D, Brown M, Zhao C, Hannah AL, Leung AC, Masuoka LK, Perez EA (2011) Final results of NKTR-102, a topoisomeraseI inhibitor-polymer conjugate in patients with pretreated metastatic breast cancer demonstrating significant antitumor activity. J Clin Oncol 29 (suppl 27):abstract 269
37.
38.
39.
Tanaka M, Furusawa H, Kamada Y, Sagara Y, Anan K, Miyara K, Kai Y, Wakamatsu S, Uga T, Tamura K, Mitsuyama S (2010) Pilot study of irinotecan and S-1 for advanced and metastatic breast cancer. Cancer Res 70(suppl 24)
40.
Hobday TJ, Stella PJ, Fitch TR, Jaslowski A, LaPlant B, Ames MM, Goetz MP, Perez EA (2008) NO436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy. J Clin Oncol 26 (May 20 suppl):abstract 1081
41.
Ma CX, Ellis MJ, Petroni GR, Lockhart AC, Naughton M, Pluard TJ, Brenin C, Picus J, Creekmore AN, Mwandoro TN, Guo Z, Cai S, Ryan C, Yarde E, Hoog J, Dancey J, Watson M, Piwnica-Worms H, Fracasso PM (2012) Clinical and correlative science results in a phase II study of UCN-01 in combination with irinotecan in recurrent triple-negative breast cancer. J Clin Oncol 30 (suppl):abstract 3047
42.
Moulder S, Mita M, Bradley C, Rocha C, Harris L (2010) A phase 1b study to assess the safety and tolerability of the PARP inhibitor iniparib in combination with irinotecan for the treatment of patients with metastatic breast cancer. Presented at SABC:abstract P6-15-01
43.
Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D (2008) Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer 113(10):2646–2654. doi:10.​1002/​cncr.​23916 PubMedCrossRef
44.
Von Hoff DD, Jameson GS, Borad MJ, Rosen LS, Utz J, Basche M, Alemany C, Dhar S, Acosta L, Barker T, Walling J, Hamm JT (2008) First phase I trial of NKTR-102 (Peg-Irinotecan) reveals early ecidence of broad anti-tumor activity in three different schedules. In: EORTC-NCI-AACR symposium on “molecular targets and cancer therapeutics” Poster no. 595, Geneva
45.
46.
Frasci G, D’Aiuto G, Thomas R, Comella P, Di Bonito M, Lapenta L, D’Aiuto M, Botti G, Vallone P, De Rosa V, D’Aniello R, Giordano R, Comella G (2005) Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline–paclitaxel–refractory breast cancer patients. Oncology 68(4–6):391–397. doi:10.​1159/​000086980 PubMedCrossRef
47.
Stathopoulos GP, Tsavdaridis D, Malamos NA, Rigatos SK, Kosmas C, Pergantas N, Stathopoulos JG, Xynotroulas J (2005) Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol 56(5):487–491. doi:10.​1007/​s00280-005-1006-3 PubMedCrossRef
48.
Katz A, Hoff PM, Simon SD, Gansl RC, Tabacof J, Abramoff R, Pietrocola M, Smaletz O, Novis Y (2003) Itinotecan and cisplatin in heavily pre-treated metastatic breast cancer patients. Proc Am Soc Clin Oncol 22: abstract 335
49.
Levine EG, Cirrincione CT, Szatrowski TP, Canellos G, Norton L, Henderson IC (1999) Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study. Am J Clin Oncol 22(3):218–222PubMedCrossRef
50.
Mainwaring PN, Nicolson MC, Hickish T, Penson R, Joel S, Slevin M, Smith IE (1997) Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer 76(12):1636–1639PubMedCrossRef
51.
Oberhoff C, Kieback DG, Wurstlein R, Deertz H, Sehouli J, van Soest C, Hilfrich J, Mesrogli M, von Minckwitz G, Staab HJ, Schindler AE (2001) Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 24(3):256–260PubMedCrossRef
52.
Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, Van’t Veer L, Viale G, Krop I, Winer E (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21(3):242–252. doi:10.​1016/​j.​breast.​2012.​03.​003 PubMedCrossRef
53.
Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588–592PubMedCrossRef
54.
Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642–1649. doi:10.​1200/​JCO.​2007.​11.​6699 PubMedCrossRef
55.
Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjostrom J, Kjaer M (2004) Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 22(12):2313–2320. doi:10.​1200/​JCO.​2004.​11.​503 JCO.2004.11.503 [pii]PubMedCrossRef
56.
Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T (2000) Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol 46(6):459–466PubMedCrossRef
57.
Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O’Shaughnessy J (2008) Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26(24):3950–3957. doi:10.​1200/​JCO.​2007.​11.​9362 PubMedCrossRef
58.
Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A (2002) Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62(1):2–8PubMedCrossRef
59.
Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12(9):1247–1254PubMedCrossRef
60.
Kusama M, Nomizu T, Aogi K, Yoshimoto M, Horikoshi N, Tabei T, Noguchi S, Miura S, Yoshimura N, Kimura M, Toyama K, Shin E (2010) Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer 17(4):233–240. doi:10.​1007/​s12282-009-0137-5 PubMedCrossRef
61.
Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29(34):4498–4504. doi:10.​1200/​JCO.​2010.​33.​9101 PubMedCrossRef
62.
Martin M, Ruiz A, Munoz M, Balil A, Garcia-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, Garcia-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodriguez CA, Adrover E, Mel JR (2007) Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8(3):219–225. doi:10.​1016/​S1470-2045(07)70041-4 PubMedCrossRef
63.
Dumez H, Awada A, Piccart M, Assadourian S, Semiond D, Guetens G, de Boeck G, Maes RA, de Bruijn EA, van Oosterom A (2006) A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. Ann Oncol 17(7):1158–1165. doi:10.​1093/​annonc/​mdl071 PubMedCrossRef
64.
Kuppens IE, Dansin E, Boot H, Feger C, Assadourian S, Bonneterre ME, Beijnen JH, Schellens JH, Bonneterre J (2006) Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clin Cancer Res 12(12):3774–3781. doi:10.​1158/​1078-0432.​CCR-05-2368 PubMedCrossRef
65.
Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C (2006) A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol 58(2):165–172. doi:10.​1007/​s00280-005-0138-9 PubMedCrossRef
66.
Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH (2005) Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemother Pharmacol 55(3):263–270. doi:10.​1007/​s00280-004-0874-2 PubMedCrossRef
67.
Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26(16):2690–2698. doi:10.​1200/​JCO.​2007.​15.​5580 PubMedCrossRef
68.
Koopman M, Knijn N, Richman S, Seymour M, Quirke P, van Tinteren H, van Krieken JHJM, Punt CJ, Nagtegaal ID (2009) The correlation between Topoisomerase-I expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer patients treated in the CAIRO study of the Dutch Colorectal Cancer Group. EJC Supplements 7:321–322
69.
Romer MU, Jensen NF, Nielsen SL, Muller S, Nielsen KV, Nielsen HJ, Brunner N (2012) TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scand J Gastroenterol 47(1):68–79. doi:10.​3109/​00365521.​2011.​638393 PubMedCrossRef
70.
Stenvang J, Smid M, Nielsen SL, Timmermans M, Rømer M, Nielsen D, Foekens J, Brünner N, Martens J (2012) Topoisomerase 1 gene copy aberrations in 52 human breast cancer cell lines and association to gene expression. Cancer Res 72(suppl)
71.
Stenvang J, Smid M, Nielsen S, Balslev E, Timmerman J, Rømer M, Nygaard S, Christensen I, Nielsen D, Foekens J, Brünner N, Martens J (2012) Topoisomerase 1 gene copy aberration is a frequent finding in clinical breast cancer samples. Cancer Res 72(suppl)
72.
Lynch BJ, Bronstein IB, Holden JA (2001) Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J 7(3):176–180PubMedCrossRef
Metadata
Title
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer
Authors
Iben Kümler
Nils Brünner
Jan Stenvang
Eva Balslev
Dorte L. Nielsen
Publication date
01-04-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2476-3

Other articles of this Issue 2/2013

Breast Cancer Research and Treatment 2/2013 Go to the issue

Clinical Trial

Impact of local surgical treatment on survival in young women with T1 breast cancer: long-term results of a population-based cohort

Epidemiology

Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women

Clinical Trial

The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse

Preclinical Study

αB-Crystallin promotes oncogenic transformation and inhibits caspase activation in cells primed for apoptosis by Rb inactivation

Brief Report

A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase

Preclinical Study

The protective effect of intermittent calorie restriction on mammary tumorigenesis is not compromised by consumption of a high fat diet during refeeding
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits